Min Jung Chang
Overview
Explore the profile of Min Jung Chang including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
49
Citations
457
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Kim M, Ryu K, Kim H, Lee H, Lim J, Kim H, et al.
Comput Biol Med
. 2025 Jan;
186:109682.
PMID: 39862467
Background: Erlotinib is a potent first-generation epidermal growth factor receptor tyrosine kinase inhibitor. Due to its proximity to the upper limit of tolerability, dose adjustments are often necessary to manage...
2.
Kim S, Kang H, Roh Y, Hahn J, Min K, Lee S, et al.
Epilepsia Open
. 2024 Nov;
10(1):243-257.
PMID: 39607729
Objective: This study aimed to evaluate the effectiveness and safety of everolimus in treating seizures associated with focal cortical dysplasia type 2 (FCD 2). Methods: A prospective, crossover, placebo-controlled clinical...
3.
Lee S, Hahn J, Kim H, Chang M
J Clin Med
. 2024 Apr;
13(5).
PMID: 38592021
(1) Background: Older patients frequently require dosing aids, such as multi-dose medication dispensing (MMD) when they experience medication regimen complexity (MRC) with increased drug use. However, the evaluations of the...
4.
Park J, Kim S, Hahn J, Kang H, Lee S, Kim H, et al.
Front Pharmacol
. 2023 Dec;
14:1197549.
PMID: 38074125
Everolimus is an inhibitor of mammalian target of rapamycin complex 1. As mutations in and , which cause partial-onset seizures associated with TSC, were found in focal cortical dysplasia type...
5.
Chae K, Seo Y, Yu Y, Chang M, Choi J
PLoS One
. 2023 Nov;
18(11):e0293655.
PMID: 37917756
Backgrounds And Aims: There are currently no studies comparing histologic remission of FDA-approved biologics for moderate to severe ulcerative colitis (UC), except for one head-to-head VARSITY trial. The current study...
6.
Lee S, Yu Y, Han E, Park M, Lee J, Chang M
Yonsei Med J
. 2023 Apr;
64(5):336-343.
PMID: 37114637
Purpose: Polypharmacy can cause drug-related problems, such as potentially inappropriate medication (PIM) use and medication regimen complexity in the elderly. This study aimed to investigate the feasibility and effectiveness of...
7.
Kang S, Yang S, Hahn J, Jang J, Min K, Wi J, et al.
J Clin Med
. 2022 Nov;
11(22).
PMID: 36431106
Background: Our objective was to determine an optimal dosage regimen of meropenem in patients receiving veno-arterial extracorporeal membrane oxygenation (V-A ECMO) by developing a pharmacokinetic/pharmacodynamic (PK/PD) model. Methods: This was...
8.
Park G, Choi B, Kang S, Kim B, Chang M
J Clin Med
. 2022 Sep;
11(18).
PMID: 36142907
This study compared the renoprotective effects of sodium−glucose cotransporter-2 (SGLT2) inhibitors and dipeptidyl peptidase-4 (DPP-4) inhibitors in patients with type 2 diabetes mellitus (T2DM). We performed a retrospective cohort study...
9.
Yun H, Chang M, Jung H, Chang V, Wang Q, Strydom N, et al.
Antimicrob Agents Chemother
. 2022 Aug;
66(9):e0189321.
PMID: 35938799
Prothionamide, a second-line drug for multidrug-resistant tuberculosis (MDR-TB), has been in use for a few decades. However, its pharmacokinetic (PK) profile remains unclear. This study aimed to develop a population...
10.
Kim H, Park G, Hahn J, Oh J, Chang M
Sci Rep
. 2022 Jun;
12(1):9703.
PMID: 35690600
We investigated the effect of angiotensin receptor neprilysin inhibitor (ARNI) on glycemic control in Korean patients. This retrospective cohort study was conducted at a single tertiary hospital. We compared the...